Skip to content

Trial Summary

A phase III, randomised study of Zanubrutinib (BGB-3111) compared with Ibrutinib in patients with relapsed/refractory chronic lymphocytic Leukemia or small lymphocytic Lymphoma.

Acronym:

BGB-3111-305

ACTRN/NCT /ethics:

 

Scientific title:

A phase III, randomised study of Zanubrutinib (BGB-3111) compared with Ibrutinib in patients with relapsed/refractory chronic lymphocytic Leukemia or small lymphocytic Lymphoma.

Sponsor / Cooperative group:

Beigene

Trial & patient characteristics

Cancer TypeLymphoma
Trial TypeTreatment
PhasePhase III
Age Range18+ years
SexBoth
Tumour StreamLymphoma
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal Investigator-
Recruitment StatusRecruitment on Hold